BACKGROUND: The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab. MATERIALS AND METHODS: A total of 245 treatment-naive metastatic colorectal cancern (mCRC) patients were retrospectively enrolled and divided into 2 groups: 145 group A patients were treated with chemotherapy in combination with bevacizumab, and 100 group B patients were treated as above without bevacizumab. RESULTS: Group A patients had better median overall survival (OS) and progression-free survival (PFS) (24.0 and 9.0 months) than group B patients (20 and 6.0 months) (p=0.033; p=0.015). In patients with low NLR, OS and PFS were significantly longer in group A patients (27 vs 18 months, p=0.001; 11 vs 7 months, p=0.017). CONCLUSIONS: We conclude that NLR, a basal cancer related inflammation marker, is associated with the resistance to bevacizumab- based treatments in mCRC patients.
BACKGROUND: The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab. MATERIALS AND METHODS: A total of 245 treatment-naive metastatic colorectal cancern (mCRC) patients were retrospectively enrolled and divided into 2 groups: 145 group A patients were treated with chemotherapy in combination with bevacizumab, and 100 group B patients were treated as above without bevacizumab. RESULTS: Group A patients had better median overall survival (OS) and progression-free survival (PFS) (24.0 and 9.0 months) than group B patients (20 and 6.0 months) (p=0.033; p=0.015). In patients with low NLR, OS and PFS were significantly longer in group A patients (27 vs 18 months, p=0.001; 11 vs 7 months, p=0.017). CONCLUSIONS: We conclude that NLR, a basal cancer related inflammation marker, is associated with the resistance to bevacizumab- based treatments in mCRC patients.
Authors: Nigar Dirican; Ahmet Dirican; Ceyda Anar; Sule Atalay; Onder Ozturk; Ahmet Bircan; Ahmet Akkaya; Munire Cakir Journal: Asian Pac J Cancer Prev Date: 2016-12-01
Authors: Apolonia Novillo; María Gaibar; Alicia Romero-Lorca; María Fuencisla Gilsanz; Laura Beltrán; Miguel Galán; Beatriz Antón; Diego Malón; Amalia Moreno; Ana Fernández-Santander Journal: World J Gastroenterol Date: 2020-04-28 Impact factor: 5.742
Authors: Stephen John Clarke; Matthew Burge; Kynan Feeney; Peter Gibbs; Kristian Jones; Gavin Marx; Mark P Molloy; Timothy Price; William H H Reece; Eva Segelov; Niall C Tebbutt Journal: PLoS One Date: 2020-03-06 Impact factor: 3.240